UbiVac
Phase 1/2At the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 8, 2025, Dr. Rom Leidnerpresented updated clinical results in a session entitled “The Dark Genome: Making Cryptic Epitopes Actionable.” His presentation included two-year overall survival data from patients treated with DPV-001 combination immunotherapy. Among PD-1–naïve patients, the median overall survival was 25.5 months, compared with 12.3 months reported for patients receiving standard-of-care pembrolizumab.
About
At the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 8, 2025, Dr. Rom Leidnerpresented updated clinical results in a session entitled “The Dark Genome: Making Cryptic Epitopes Actionable.” His presentation included two-year overall survival data from patients treated with DPV-001 combination immunotherapy. Among PD-1–naïve patients, the median overall survival was 25.5 months, compared with 12.3 months reported for patients receiving standard-of-care pembrolizumab.
Funding History
3Total raised: $2.8M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile